Completed OBSERVATIONAL NCT00467311

Cystatin C as an Early Marker of Contrast-Medium Nephropathy in Cardiac Catheterization Patients

Diagnostic, Transversal, Comparative, Not Randomized Trial for the Evaluation of Cystatin C as an Early Marker of Contrast-Medium Nephropathy in High-and-Intermedium-Risk Patients Undergoing to Cardiac Catheterization

Sponsor: National Heart Institute, Mexico

Conditions Acute Renal Failure Contrast Induced Nephropathy

Updated 6 times since 2017 Last updated: May 6, 2008 Started: Dec 31, 2006 Primary completion: Dec 31, 2007 Completion: Apr 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Acute Renal Failure and Contrast Induced Nephropathy, this trial is completed. The trial is conducted by National Heart Institute, Mexico and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Heart Institute, Mexico

Data source: National Heart Institute, Mexico

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mexico City, Mexico